Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Total Debt (2017 - 2025)

Serina Therapeutics' Total Debt history spans 9 years, with the latest figure at $2.9 million for Q3 2025.

  • For Q3 2025, Total Debt fell 74.11% year-over-year to $2.9 million; the TTM value through Sep 2025 reached $2.9 million, down 74.11%, while the annual FY2022 figure was $18.1 million, 195.56% up from the prior year.
  • Total Debt for Q3 2025 was $2.9 million at Serina Therapeutics, down from $11.2 million in the prior quarter.
  • Across five years, Total Debt topped out at $33.0 million in Q2 2023 and bottomed at $2.2 million in Q3 2023.
  • The 5-year median for Total Debt is $10.9 million (2022), against an average of $12.4 million.
  • The largest annual shift saw Total Debt surged 402.7% in 2024 before it plummeted 74.11% in 2025.
  • A 5-year view of Total Debt shows it stood at $6.1 million in 2021, then soared by 195.56% to $18.1 million in 2022, then crashed by 87.76% to $2.2 million in 2023, then soared by 402.7% to $11.2 million in 2024, then tumbled by 74.11% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Total Debt are $2.9 million (Q3 2025), $11.2 million (Q3 2024), and $11.1 million (Q2 2024).